Health
‘Liquid gold’ could bring new hope to multiple sclerosis patients, study suggests: ‘Profound benefit’
Researchers may have hit “gold” when it comes to the treatment of multiple sclerosis.
An experimental medication called CNM-Au8 — a drinkable liquid with gold nanocrystals — has shown promising results in clinical trials in terms of improvements in MS symptoms.
The “catalytically active” liquid, developed by Clene Nanomedicine in North East, Maryland, can cross the blood-brain barrier to help improve cellular energy and restore neurological function, according to researchers.
BREAKTHROUGH FOR MULTIPLE SCLEROSIS SUFFERERS MAY INVOLVE HELPFUL HORMONE: ‘PATIENTS SHOULD REMAIN OPTIMISTIC’
Doctors at the University of Sydney presented the Phase 2 clinical trial findings at the American Academy of Neurology’s annual meeting earlier in April 2024.
The clinical trials included 78 patients who had relapsing multiple sclerosis.
An experimental medication called CNM-Au8 — a drinkable liquid with gold nanocrystals — has shown promising results in clinical trials for improving MS symptoms. (Clene Nanomedicine)
The gold liquid suspension was found to have a “profound clinical benefit,” with the patients experiencing physical improvements not achieved in prior trials.
A need for new MS drugs
Multiple sclerosis is an autoimmune disease of the central nervous system, brain, spinal cord and optic nerve.
In people with MS, white cells called lymphocytes infiltrate the central nervous system and trigger inflammation.
That often causes them to feel off balance or lose their vision, according to Dr. Robert C. Sergott, chief of the neuro-ophthalmology service at Wills Eye Hospital and professor of ophthalmology, neurology and neurosurgery at Sidney Kimmel Medical College in Philadelphia.
The MS medications that are currently available work by addressing inflammation — but there is a subset of patients that continue to experience symptoms even without inflammation, he said. This is a condition called progression independent of relapse activity (PIRA).
RESEARCHERS FIND SOURCES OF FOUR BRAIN DISORDERS, WHICH COULD LEAD TO NEW TREATMENTS
“This is a non-inflammatory component of the disease, where patients would worsen in vision and cognitive abilities,” Sergott, who was involved in the clinical trial for CNM-Au8, told Fox News Digital.
Researchers suspected that something to do with mitochondria — parts of cells that are responsible for supplying those cells with energy — was causing these patients’ symptoms.
“The theory was that if we could give the mitochondria an extra boost, the neurons, axons and other cells in the central nervous system may work better,” said Sergott.
The “catalytically active” liquid can cross the blood-brain barrier to help improve cellular energy and restore neurological function, according to researchers. (Clene Nanomedicine)
“In other words, maybe these cells aren’t dead, but they’re hibernating.”
Gold nanoparticles were originally used to treat rheumatoid arthritis many years ago, according to Sergott.
“Clene innovated a novel electrochemical method to make gold particles and [got] them to a very highly purified nanoparticle state — into very small particles, so they can get through the blood-brain barrier to the cells that need it to work better.”
‘Significant result’
Among the 78 participants in the randomized clinical trial performed in Australia, two-thirds of them received the gold treatment and the other third received a placebo over a three-year period.
“We had hoped to enroll more patients, but COVID intervened,” Sergott said.
Neither the patients nor the neurologist overseeing the trial knew who was receiving the actual medicine.
“We’re very encouraged and ready to take the next step. It’s going to help a lot of people.”
“Patients saw a clinical improvement in the function of their vision and their cognitive ability,” Sergott reported.
Doctors also noted an improvement in the electrophysiology, he said — “the patients’ MRIs looked better, which is a special measure.”
“The theory was that if we could give the mitochondria an extra boost, the neurons, axons and other cells in the central nervous system may work better,” a doctor said. (iStock)
The patients who received the medicine had no decline in retinal thickness, but those on the placebo did see a decline, he said.
“This was a very significant result, and gives us a lot of hope that we may be able to help patients who have deficits from MS and have had progression independent of relapse activity — or maybe they had an attack and didn’t get complete recovery from it,” Sergott said.
TO LIVE LONGER, DO THESE 5 THINGS EVERY DAY, SAYS A BRAIN HEALTH EXPERT
None of the trial participants reported any adverse side effects, he said.
“The safety profile is excellent,” Sergott told Fox News Digital. “I can’t say this doesn’t have any side effects — but no patients discontinued the trial because of a side effect that was significant.”
None of the trial participants reported any adverse side effects from the gold treatment, the researchers said. (iStock)
With the successful Phase 2 trials complete, researchers are now looking ahead to Phase 3 trials.
“We’re very encouraged and we’re ready to take the next step,” said Sergott. “It’s really going to help a lot of people.”
Patients taking CNM-Au8 would still need to continue with the standard regimen of anti-inflammatory medications, the doctor noted.
CAN WE REVERSE ALZHEIMER’S DISEASE? EXPERTS SUGGEST ‘NEW PARADIGM’ FOR COMBATING DEMENTIA
Looking ahead, there is the potential for the “liquid gold” medication to help treat symptoms of other neurological disorders, including amyotrophic lateral sclerosis (ALS), Alzheimer’s and Parkinson’s, according to Sergott — but the focus is on MS for now.
“We don’t want to get too far ahead of ourselves, but there is plenty of information to support trying this in other diseases.”
Patient shares his experience
Damian Kunko of Arlington, Virginia, was one of the MS patients who participated in the trial. He had previously taken disease-modifying therapies that included Zeposia and Tecfidera.
“These drugs reduced the risk of relapse, but had no effect on progressive symptom worsening,” Kunko told Fox News Digital.
Damian Kunko of Arlington, Virginia, was one of the MS patients who participated in the trial. (Clene Nanomedicine)
Kunko’s primary symptoms included heat intolerance, foot drop/limping, numbness, balance issues, double vision and minor decline of cognitive function and energy.
After four months of taking CNM-Au8, Kunko found that his walking speed was 14% faster.
“I was also able to do short 5-10-yard jogs without falling, which was impossible prior to taking [the drug],” he said.
“The best ‘side effect’ was knowing that this drug will fix my MS issues.”
“I also experienced improved visual acuity, less severe double vision, zero cognitive fog issues and increased energy levels.”
Later in the trial, Kunko was able to withstand high heat and humidity for several hours and did not experience any double vision, foot drop, excessive numbness or fatigue issues.
“It was nice to be able to go up and down stairs without having to hold the railing,” he said.
Clinical improvements were seen in both the visual system and on patients’ MRI scans, according to doctors. (iStock)
The patient said he did not experience any negative side effects or adverse reactions.
“The best ‘side effect’ was knowing that this drug will fix my MS issues,” Kunko said.
“I am very disappointed that this therapy is not yet commercially available for those who need to restore function and alleviate MS symptoms,” he added.
Doctors weigh in
Dr. Marc Siegel, clinical professor of medicine at NYU Langone Medical Center and a Fox News medical contributor, was not involved in the drug’s development but commented on the potential of gold therapies.
“Gold-containing analogies have long been treatments for rheumatoid arthritis — what is known as disease-modifying anti-rheumatic drugs,” he told Fox News Digital.
“And now gold-containing agents are being studied in MS and ALS.”
While the latest study is small, Siegel said, it “looks promising in terms of modifying disease and improving thinking and vision, which can be affected in the early stages of MS.”
He added, “More research with larger numbers needs to be done to be conclusive.”
“Gold-containing analogies have long been treatments for rheumatoid arthritis — what is known as disease-modifying anti-rheumatic drugs,” one doctor told Fox News Digital. (Clene Nanomedicine)
Dr. James Kuo, vice president of R&D at Silo Pharma in New Jersey, was also not involved in the drug’s development but said the trial results are “encouraging.”
“These new long-term results from the Phase 2 clinical trial support the therapeutic hypothesis that CNM-Au8 is remyelinating nerve cells in MS patients,” Kuo told Fox News Digital.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“What is further encouraging is that both the primary and secondary endpoints showed continued improvement,” he added. “There was physiological enhancement in the visual neural pathway, a biomarker of nerve health. Further MRI measurements support remyelination occurring.”
“If further clinical data supports these initial findings, MS patients could well have a new, well-tolerated oral therapy that is not based upon immune system modulation.”
Ensuring proper dosing, monitoring patients for potential side effects and following proper follow-up protocols are “essential aspects” of bringing this therapy into clinical practice, a doctor said. (iStock)
Dr. Sameea Husain Wilson, director of movement disorder neurology at Marcus Neuroscience Institute, at Boca Raton Regional Hospital in Florida, said that CNM-Au8 offers hope for patients and their families.
“It shows promise in the possibility of slowing disease progression, improving symptoms and enhancing quality of life,” he told Fox News Digital in a statement.
Wilson noted, however, that it is important to “approach the drug development cautiously and be aware of potential risks.”
“The complexity of neurodegenerative diseases necessitates a comprehensive understanding of individual patient profiles,” he said.
“It’s essential to recognize that not all patients may respond uniformly to treatment, and factors such as disease stage, comorbidities and genetic predispositions may influence outcomes.”
Ensuring proper dosing, monitoring patients for potential side effects and following proper follow-up protocols are “essential aspects” of bringing this therapy into clinical practice, Wilson added.
For more Health articles, visit www.foxnews.com/health.
Health
Finding the sleep ‘sweet spot’ could help you live longer, study suggests
NEWYou can now listen to Fox News articles!
How long you sleep could be linked to how long you’ll live.
A new study, published in the journal Nature, found that people who slept too little or too long showed signs of “older biology.”
Researchers from Columbia University in New York used global biobank data from about 500,000 people who disclosed self-reported sleep duration in a 24-hour period, including naps.
DEEP SLEEP CAN KEEP TWO BIG HEALTH PROBLEMS AT BAY, NEW STUDIES SUGGEST
Reported sleep times were compared with 23 biological aging clocks, estimating whether various parts of the body looked biologically older or younger than the individual’s actual age.
Short and long sleep were both linked with signals of a higher biological age. They were also associated with a higher risk of future diseases and all-cause mortality, the researchers found.
According to study results, short sleep and long sleep were both linked with signals of higher biological age. (iStock)
In nine of the aging clocks, the researchers found “statistically significant” links between sleep and aging, including in the brain, heart, immune system and skin.
Those with the “lowest biological age gap” were women who slept for 6.5 to 7.8 hours and men who slept for 6.4 to 7.7 hours, according to the study.
Longer sleep had a stronger link to psychiatric-related outcomes, while short sleep had more physical impacts on cardiovascular, metabolic, musculoskeletal, psychiatric, neurological, pulmonary and gastrointestinal conditions.
HERE’S WHY 90% OF AMERICANS DON’T SLEEP THROUGH THE NIGHT, ACCORDING TO EXPERT
The U-shaped results also showed that shorter sleep led to a 50% higher relative risk for all-cause mortality, while longer sleep had about a 40% higher risk.
The researchers noted that self-reported sleep poses a limitation to the study. As it was observational in design, it does not prove that sleeping exactly six to eight hours will slow aging.
Both women and men who slept roughly six to eight hours showed the lowest signals for biological aging. (iStock)
Saema Tahir, MD, a New York-based board-certified sleep medicine physician, reflected on these findings in an interview with Fox News Digital.
“Sleep is really when the body does its most critical repair work, including cellular restoration, immune regulation, hormonal balance, and even clearing out metabolic waste from the brain through what we call the glymphatic system,” said Tahir, who was not involved in the study.
AGING PROCESS COULD ACCELERATE DUE TO ‘FOREVER CHEMICALS’ EXPOSURE, STUDY FINDS
“When sleep is consistently too short or too long, those processes get disrupted. Over time, that disruption accumulates at the cellular level.”
This effect is proven in increased inflammatory markers and cellular changes, which are “hallmarks of accelerated aging,” Tahir noted.
“So, the relationship isn’t just correlational; there are real physiological mechanisms connecting poor sleep to the body aging faster than it should.”
“Sleep is really when the body does its most critical repair work,” the doctor noted. (iStock)
Tahir cautions her patients not to treat the six- to eight-hour recommendation as a “rigid prescription,” as sleep is individualized.
For example, a healthy 25-year-old and a 70-year-old with cardiovascular disease have “very different sleep architecture and needs,” according to the expert.
DO WOMEN NEED MORE SLEEP THAN MEN? HERE’S WHAT EXPERTS THINK
“What I tell my patients is to use that range as a starting framework, but pay attention to how you feel,” she advised. “Are you waking up refreshed? Can you stay alert throughout the day without caffeine propping you up? Those functional cues matter just as much as the number on the clock.”
For certain people, like pregnant women, athletes and people recovering from illness, these sleep needs can shift “considerably.”
As sleep is individualized, a rigid six- to eight-hour framework may not work for everyone. (iStock)
“Sleep duration is important, but … getting adequate sleep and REM sleep that allows our bodies to heal, clear, process and repair is much more important,” Tahir said.
Regardless of sleep time, those who don’t achieve quality sleep often struggle, she shared.
CLICK HERE FOR MORE HEALTH STORIES
“I’ve seen patients who log seven hours but spend most of that time in light sleep, barely touching the deep slow-wave or REM stages that are most restorative,” Tahir said. “They age just as poorly, sometimes worse, than someone getting six hours of genuinely consolidated, high-quality sleep.”
Deep sleep is the phase when growth hormone is released and tissue repair peaks, and REM sleep is “critical” for cognitive health and emotional regulation, according to the expert.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“So, chasing hours without addressing sleep fragmentation, sleep apnea or poor sleep architecture is missing the bigger picture,” she said.
The takeaway from this study, according to Tahir, is that sleep is not a “lifestyle luxury,” but a “biological necessity with measurable consequences for how we age and how healthy we are.”
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
There’s still a cultural tendency to see sleep deprivation as a “badge of productivity,” which she pushes back against. “But I also want people to avoid the other extreme — health anxiety about their sleep can actually make sleep worse.”
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
The sleep expert concluded that “consistent, good-quality sleep is one of the most accessible tools we have for healthy aging.”
“It doesn’t require a prescription or expensive intervention — it requires prioritization.”
Health
‘Wild West’ peptide craze surges beyond GLP-1s as FDA faces pressure to ease access
NEWYou can now listen to Fox News articles!
As GLP-1 weight-loss medications gain traction, the peptide market is experiencing a surge in interest.
A variety of peptides — commonly marketed for weight loss, muscle building, injury recovery and other uses — have emerged as largely unregulated drugs sold through both licensed compounding pharmacies and unverified vendors.
The U.S. Food and Drug Administration is set to evaluate whether to loosen regulations on several peptides during a meeting this summer.
THINKING ABOUT PEPTIDES? DOCTORS REVEAL KEY DOS AND DON’TS AS ‘WILD WEST’ MARKET GROWS
Peptides are short chains of amino acids — the building blocks of proteins — that play key roles in biological functions, according to the National Institutes of Health. Peptide drugs are lab-made versions of natural molecules in the body that are designed to mimic or influence biological signals to treat disease, experts say.
GLP-1s are “incredibly effective at what they do when it comes to changing body composition, benefiting metabolic health, cardiovascular health [and] neurologic health,” the expert said. (iStock)
Though the peptide market has been described as the “Wild West,” demand remains strong, potentially challenging pharmaceutical giants that dominate the GLP-1 market.
Dr. Alex Tatem, an Indiana-based board-certified urologist with expertise in men’s health and peptides, discussed how “life-changing” GLP-1s kicked off the rise of peptides.
“These were all medications that were designed to help people live well and live as healthy as possible.”
“They are incredibly effective at what they do when it comes to changing body composition, benefiting metabolic health, cardiovascular health [and] neurologic health,” he said. “These are truly miracle compounds, and as a result we’ve seen an explosion of interest – not just on the pharmaceutical side or the doctor’s side, but from the general public.”
According to Tatem, the challenge is that nearly all commercial GLP-1 products are administered in a single-dose weekly pen, which works for the “overwhelmingly majority” of patients, but not for everyone.
OZEMPIC ‘MICRODOSING’ IS THE NEW WEIGHT-LOSS TREND: SHOULD YOU TRY IT?
“There are patients I can prescribe tirzepatide to and they can do OK with a once-a-week [dose], but they end up developing nausea with that initial injection – and then by the end of the week, they’re hungry again.”
Because some patients respond better to smaller, more frequent doses — an option not offered by commercial drugs — compounding, or the customization of medications, has grown in popularity, Tatem said.
Several GLP-1 weight loss medications have been approved by the FDA with positive results from consumers. (iStock)
“We’ve had compounding pharmacies that have now developed compounded versions of semaglutide and tirzepatide that allow that sort of dosing flexibility,” he said.
“The reason compounders had to do this was because there was so much demand for GLP-1s that there was actually a national shortage.”
Current legislation allows compounders to step in during widespread national shortages, according to Tatem, prompting the industry to invest millions of dollars into developing and manufacturing these drugs.
PEPTIDES MAY SOON BE EASIER TO GET AMID RFK JR.’S PUSH, BUT EXPERTS WARN OF RISKS
Once commercial pharmaceutical companies could catch back up, compounders continued making these medications in smaller batches for custom doses, allowing for more patient accessibility.
“That creates a huge clash between commercial pharmaceutical companies and compounders, because commercial pharmaceutical companies view that as an infringement of their property,” Tatem noted.
The expert noted a “huge clash” between pharmaceutical companies and compounding pharmacies in peptide production. (iStock)
Tatem raised concerns about the FDA’s regulation of compounding pharmacies, warning that it could limit patients’ access to customized medications.
“That is a real concern for clinicians like me who really care more about patient access, making sure we can get the right medication to the right patients at the right time,” he said.
RFK JR. BACKS EASIER PEPTIDE ACCESS FOR WELLNESS AS DOCTORS RAISE RED FLAGS
Some peptides have been widely administered for more than a decade without major health complications like toxicity or cancer, according to Tatem.
“These are compounds that haven’t gone through the full FDA approval process that you would normally see for a commercial drug, [yet] we didn’t see anything adverse,” he said.
The FDA plans to consider loosening restrictions on several peptides during a summer 2026 meeting. (Issam Ahmed/AFP)
In September 2023, the FDA “quietly” tightened regulation of 19 peptides, making them illegal to manufacture and cutting off patient access.
“They seemed to be working and seemed to be efficacious for patients, and all of a sudden they were banned, which inadvertently ended up contributing to this surge in interest,” Tatem said. “We kind of saw the same thing happen with peptides that we saw with prohibition.”
CLICK HERE FOR MORE HEALTH STORIES
While the rising popularity of GLP-1 drugs has fueled growing public and regulatory interest in peptides, most of the so-called “trendy” peptides still are not available by prescription, according to Tatem.
They may help with injury recovery, skin rejuvenation, sleep improvements and boosting of natural growth hormones, he said.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“These were all medications that were designed to help people live well and live as healthy as possible,” the doctor told Fox News Digital. “And in reality, that was also their downfall in the American healthcare system, because if you are going to get a drug approved and to market, it has to treat a disease state.”
“These were all medications that were designed to help people live well and live as healthy as possible,” Tatem told Fox News Digital. (iStock)
Tatem confirmed that he’s seen a shift in patients confronting more than just baseline ailments, seeking advice on how to feel their best through new modes like testosterone therapy.
“The desire to function at our highest level is something that we all feel,” he said.
While nothing replaces the fundamentals — getting eight hours of sleep, eating a high-protein diet and maintaining a fitness routine that blends resistance training and cardio — Tatem said individualized treatments such as peptides may help support those healthy habits.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
“If you end up pulling a tendon or pulling a hamstring, and you’re just now starting to get some momentum in the gym, that’s really where peptides start to step in,” he added.
Experts advise consumers to avoid gray-market products, to work only with qualified physicians and reputable pharmacies, and to treat peptides as part of a broader health plan — not a shortcut or risk-free supplement.
Semaglutide (GLP-1) weight-loss drug Wegovy, made by pharmaceutical company Novo Nordisk, is designed to treat type 2 diabetes, but is widely known for its effect on weight loss. Picture date: Wednesday, October 16, 2024. (James Manning/PA Images via Getty Images)
In a statement shared with Fox News Digital, a Novo Nordisk spokesperson said the drugmaker is committed to working with regulators, law enforcement and “other key stakeholders” to ensure “affordable access to safe, effective and FDA-approved GLP-1 obesity medication like Wegovy and to protect patients from unapproved and untested knockoff drugs.”
“The desire to function at our highest level is something that we all feel.”
“Novo Nordisk supports FDA’s recent thorough scientific analysis and conclusion that there is no medical basis or clinical need for the continued mass compounding of unapproved semaglutide and liraglutide drugs,” they went on.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“The agency’s decision reaffirms that compounding is meant to be a rare and limited exception to FDA’s gold-standard drug approval framework that ensures that medicines in the U.S. are safe and effective.”
Fox News Digital reached out to the FDA and Eli Lilly for comment.
Health
New obesity treatment may help preserve muscle during weight loss
NEWYou can now listen to Fox News articles!
During a recent episode of her podcast, Gwyneth Paltrow spoke with neuroscientist Dr. Andrew Huberman about retatrutide, a new advancement in GLP-1 (glucagon-like peptide-1) therapies.
In recent years, GLP-1 receptor agonists have become a major focus in discussions around biohacking, longevity and wellness – but they’re not without a multitude of side effects.
Huberman noted that while first-generation weight-loss drugs curbed users’ appetites, they frequently plunged them into massive, rapid caloric deficits.
‘NEXT OZEMPIC’ AIMS TO DELIVER 30% WEIGHT LOSS WITH FEWER SIDE EFFECTS
Without aggressive resistance training, a high percentage of that lost weight came directly from lean muscle. “People would lose a ton of weight, but they would also lose muscle mass,” Huberman told Paltrow.
In clinical trials, retatrutide is administered as a once-weekly subcutaneous injection. (iStock)
That is where retatrutide comes in, he said. Unlike older single- or dual-action medications, retatrutide is a triple agonist.
That means it activates the body’s receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon – three hormones involved in regulating blood sugar, appetite and metabolism.
WEIGHT-LOSS EXPERTS PREDICT 5 MAJOR TREATMENT CHANGES LIKELY TO EMERGE IN 2026
“Retatrutide is a more mild agonist of GLP-1,” said Huberman. “It also increases glucagon and … GIP. So, it hits three different pathways, each a bit more subtly.”
In clinical trials, retatrutide is administered as a once-weekly subcutaneous injection.
Without aggressive resistance training, a high percentage of lost weight can come directly from lean muscle mass, said Andrew Huberman. (iStock)
Because of its balanced, multi-receptor approach, Huberman said the drug has a “lower side effect profile” while still allowing people to lose up to a third of their body weight “across a year or so.”
NEW OZEMPIC-ALTERNATIVE DIABETES PILL BURNS FAT WITHOUT MUSCLE LOSS, STUDY SUGGESTS
Most importantly for fitness and longevity advocates, the doctor pointed out that retatrutide seems to have “some muscle sparing effect.”
Because the drug is still moving through official pipelines, a massive gray market of compounding pharmacies and online peptide suppliers has cropped up to meet the growing demand.
Retatrutide is an investigational molecule that is legally available only to participants in Lilly’s clinical trials, according to Lilly’s website, and the company is currently “evaluating its safety and efficacy” in these clinical studies. (iStock)
Huberman issued a strict warning regarding these unregulated online sources, noting that these options “can say 99% purity, but that 1% means there could be some LPS,” referring to lipopolysaccharides, a type of bacterial toxin.
CLICK HERE FOR MORE HEALTH STORIES
“LPS will cause inflammation,” he cautioned. “One injection isn’t gonna do it, but multiple injections over time, I could see where that could become problematic.”
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
Paltrow echoed the safety concerns, comparing the current “wild-west” peptide craze to the landscape of supplements in the 90s, “where there’s really no third-party testing and it’s kind of word of mouth.”
“Multiple injections over time, I could see where that could become problematic.”
Both agreed that anyone exploring these therapies should avoid unverified online sources and prioritize working with a medical doctor.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Retatrutide is an investigational molecule that is legally available only to participants in Lilly’s clinical trials, according to the manufacturer’s website. The company is currently “evaluating its safety and efficacy.”
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
The drug has not been reviewed or approved by any regulatory agency, and no one should consider taking anything claiming to be retatrutide outside of a Lilly-sponsored clinical trial, experts advise.
-
Massachusetts5 minutes agoMassachusetts Senate looks to reduce wrong-way driving, honor fallen MSP trooper Kevin Trainor
-
Minnesota11 minutes agoWhere to watch Minnesota Twins vs Boston Red Sox: TV channel, start time, streaming for May 22
-
Mississippi17 minutes agoMississippi Lottery Mississippi Match 5, Cash 3 results for May 21, 2026
-
Missouri23 minutes agoColombian national sentenced to 25 years for raping, impregnating 12-year-old girl in Missouri
-
Montana29 minutes agoMontana transportation leaders address aging infrastructure at Billings summit
-
Nebraska35 minutes agoOSU Softball: Cowgirls’ Super Regional Opener Against Nebraska Postponed for Weather
-
Nevada41 minutes agoNevada postal workers launch national vote-by-mail ad campaign
-
New Hampshire47 minutes agoNashua Man Had Baggies Of Cocaine, Fentanyl, And Meth Inside Coalition Apartment Building, Concord Cops Say